Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cinacalcet and contrast-enhanced ultrasound in haemodialysis patients with secondary hyperparathyroidism
ChiCTR1900020610Phase 4Not yet recruiting
- Sponsor
- China-Japan Friendship Hospital
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of cinacalcet in secondary hyperparathyroidism (SHPT) (2 arms), sponsored by China-Japan Friendship Hospital. Primary endpoints: Intact parathyroid hormone, Serum calcium and 6 more. Planned start Mar 2019; status: not yet recruiting.
02
Drugs
cinacalcet
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on ChiCTR1900020610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900020610.